Every 8-K that ASP Isotopes Inc. (ASPI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ASPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASPI filings page.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. has extended the deadline to complete its planned acquisition of Renergen Limited, giving more time to meet closing conditions. Under the proposed South African scheme of arrangement, Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The longstop date has been moved from September 30, 2025 to November 28, 2025 to obtain remaining regulatory approval and third-party consents. Implementation of the scheme still depends on approval from the Financial Surveillance Department of the South African Reserve Bank, and both companies continue to work toward timely approval.
ASP Isotopes Inc. reported that its Board of Directors increased its size to seven members and elected Ralph L. Hunter as a Class II director, effective September 8, 2025. His term will run until the Company’s 2027 annual meeting of stockholders or until earlier resignation or removal, and he was also named to the Board of Managers of Quantum Leap Energy LLC, a wholly owned subsidiary.
Hunter, age 60, has over 35 years of nuclear power generation experience, including leadership roles at RC Nuclear Consultants, Orion Nuclear Energy, and Constellation-related nuclear development entities, as well as service on the U.S. Civil Nuclear Trade Advisory Committee. In connection with his election, he received an award of 10,470 shares of restricted stock under the 2022 Equity Incentive Plan, vesting in full on the one-year anniversary of the grant date, and will be compensated under the Company’s non-employee director compensation policy.
ASP Isotopes Inc. filed a current report to disclose that it issued a letter to shareholders dated September 2, 2025. The company is furnishing this shareholder letter as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is intended to provide broadly available information to the market. The filing specifies that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other SEC documents if specifically referenced.
ASP Isotopes Inc. reports it will host a corporate access event for South African investors ahead of an anticipated secondary listing of its common stock on the Johannesburg Stock Exchange, with trading on the JSE Main Board expected to begin on August 27, 2025, while retaining its primary Nasdaq listing and not raising new capital in connection with the listing. The company provides operational updates across several isotope programs in Pretoria, including commercial production of Silicon-28, where first enriched samples were shipped to a U.S. customer in August 2025, and Ytterbium-176, where enrichment has reached up to 92.4% and the first fully enriched batch is expected by the end of August 2025 with shipments to follow.
The Ytterbium-176 plant is running in batch mode and has had a 3–4 week delay in equipment for semi-continuous processing, shifting that transition to late third or early fourth quarter 2025 from prior late August guidance. The company has obtained initial permits to import controlled laser equipment for Nickel-64, Gadolinium-160 and Zinc-68 and is accelerating enrichment facility plans. Its Carbon plant, originally prepared for Carbon-14, is now enriching Carbon-12 to 99.99% for a U.S. customer, with first commercial product now expected in September 2025 after a regulatory-related delay, and demand for Carbon-12 is described as significantly higher than for Carbon-14.
ASP Isotopes reiterates expectations to initiate a spin-out of its Quantum Leap Enrichment subsidiary as a standalone public company during the second half of 2025 and continues to anticipate closing the Renergen acquisition in the third quarter of 2025, in each case subject to required approvals and consents. Company, QLE and Renergen representatives also plan to participate in a RedChip conference call on August 28, 2025.
ASP Isotopes Inc. reported that it and its subsidiary, Quantum Leap Energy LLC, entered into a Memorandum of Understanding with Fermi America for a U.S. joint venture. The parties intend to collaborate on the research, development and construction of an advanced nuclear fuel research and production facility at the planned 11GW HyperGrid Campus in Carson County, Texas.
The company disclosed this arrangement through a press release dated August 15, 2025, which is attached as an exhibit and incorporated by reference, except for three specified paragraphs.
ASP Isotopes Inc. (ASPI) filed an 8-K disclosing Item 8.01 – Other Events. The company announced, via the attached 8-Aug-2025 press release, its expected commencement of a dual listing on the Johannesburg Stock Exchange (JSE). Management believes the additional listing will complement the existing Nasdaq quotation under ticker ASPI. No financial statements, guidance, or transactional details were provided in the filing. Exhibit 99.1 contains the full release (except its 6th-7th paragraphs), while Exhibit 104 supplies the Inline XBRL cover page data.
The dual-listing plan may widen ASPI’s investor base, improve liquidity and brand visibility in South Africa, but will also subject the company to JSE regulatory requirements and incremental compliance costs. No timeline, capital raise, or pricing information was included.
ASP Isotopes Inc. (ASPI) disclosed a material definitive agreement on 28 Jul 2025. The company is investing $5 million to acquire 2 million Series Seed-1 Preferred shares of privately held IsoBio, Inc. at $2.50 per share.
- Strategic fit: IsoBio develops antibody-isotope conjugate radiotherapeutics; ASPI gains exposure to oncology applications that can expand its isotope value chain.
- Governance rights: ASPI secures 1 of 3 IsoBio board seats, broad veto rights over major corporate actions, and weighted-average anti-dilution protection.
- Conversion terms: Preferred is convertible 1:1 into IsoBio common at $2.50, automatically upon ≥ $50 m IPO or 2/3 holder consent; shares are non-redeemable.
- Ancillary agreements: Investors’ Rights, ROFR/Co-Sale, and Voting pacts grant ASPI demand registration, first-offer rights, and opportunity to buy stock before key holders sell.
- Related-party aspect: ASPI CEO Paul Mann and director Todd Wider are also designated IsoBio directors, creating potential conflicts but ensuring oversight.
- Next steps: Management will discuss IsoBio on a 30 Jul 2025 investor call; slide deck filed as Exhibit 99.1.
No immediate financial results were provided; cash outflow and future dilution depend on IsoBio’s capital needs and exit timeline.
ASP Isotopes Inc. (Nasdaq: ASPI) filed an 8-K dated 28 Jul 2025 to disclose a joint press release with IsoBio, Inc. announcing IsoBio’s initial Series Seed financing. The funds will be used to advance IsoBio’s proprietary Antibody-Isotope Conjugate platform (AICs TM) aimed at oncology indications.
The companies will host an investor webcast on 30 Jul 2025 at 10:00 a.m. ET to discuss the collaboration. No dollar amount, valuation or ownership details were provided in the filing. The press release is furnished as Exhibit 99.1 (excluding its fifth and sixth paragraphs). No other items, financial statements or pro-forma data accompanied the report.
For ASPI, the disclosure signals strategic expansion into radiopharma-enabled biologics but carries limited immediate financial visibility. The filing is informational and does not amend prior guidance or trigger accounting changes.
On 23 Jul 2025 ASP Isotopes Inc. (ASPI) executed an Underwriting Agreement with Cantor Fitzgerald covering a registered direct offering of 7,500,000 common shares at $8.00 each. The underwriters will acquire the shares at $7.52, reflecting customary underwriting fees.
ASPI projects net proceeds of ≈ $56.2 million after commissions and expenses. Closing is slated for 25 Jul 2025, subject to standard conditions, under the company’s effective Form S-3 shelf (File No. 333-286860) and a related Rule 462(b) registration statement.
Simultaneously, the company terminated its unused $25 million at-the-market Equity Distribution Agreement with Canaccord Genuity, opting instead for the fully underwritten raise. Exhibits include the underwriting agreement (1.1), Blank Rome LLP legal opinion (5.1), and a pricing press release (99.1).
On July 11, 2025, ASP Isotopes Inc. (NASDAQ: ASPI) filed a Form 8-K (Item 8.01) to disclose that shareholders of Renergen Limited have approved the scheme of arrangement for ASP Isotopes’ proposed acquisition. The approval eliminates a major condition precedent and materially advances the transaction toward closing. A press release describing the vote is attached as Exhibit 99.1 (the fifth and sixth paragraphs are expressly excluded from incorporation by reference).
The filing contains no purchase price, financing structure, or anticipated closing timetable, and it includes no additional financial statements under Item 9.01 beyond the press-release exhibit. Accordingly, the report functions primarily as a regulatory notice highlighting a positive milestone in ASP Isotopes’ M&A strategy rather than providing quantitative information.